Joint cavity drug administration method, and use thereof
By administering therapeutic agents of specific compounds to the joint cavity and adopting multiple dosing frequencies and durations, the problems of poor PJI treatment and antibiotic resistance are solved, and effective control of infections around joint prosthesis and patient life are achieved. Improvement of quality.
Patent Information
- Application Number
- PCT/CN2023/096858
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-29
- Publication Date
- 2024-12-05
AI Technical Summary
The prior art has problems such as poor treatment effect, difficulty in controlling repeated infections, strong antibiotic resistance, and lack of unified dosing standards in the treatment of periprosthetic infections (PJI), which leads to long-term pain in patients and high medical expenses.
By administering therapeutic agents containing specific compounds to the joint cavity, methods of different dosing frequencies and durations, including frequency of 1 day to 6 months, single injection or multiple injections, including frequency of daily, every 2 days, every 3 days, etc., for 1 day to 6 months, single injection or multiple doses Injection, combined with other drugs and carriers, is used to prevent or alleviate infections around joint prosthesis.
It significantly reduces the number of colonies infected around the joint prosthesis, improves synovial inflammation, improves treatment effect, reduces patient pain and medical expenses, and provides a non-surgical antibacterial treatment method.
Smart Images

Figure CN2023096858_05122024_PF_FP_ABST
Abstract
Description
Joint cavity administration method and use thereof Technical Field
[0001] The present application relates to the field of biomedicine, and specifically to a method for preventing or treating diseases by administering drugs into the joint cavity. Background Art
[0002] Artificial joint replacement, which involves surgically implanting a prosthesis to replace a joint that is painful and dysfunctional due to arthritis, joint disease, osteoarthritis, rheumatoid arthritis, and other conditions, is becoming widely used clinically as an effective treatment. Prosthetic joint infection (PJI) is a serious complication after total hip arthroplasty (THA) and total knee arthroplasty (TKA), potentially leading to complete surgical failure, joint dysfunction, and even amputation or death in severe cases. The pathogenesis of PJI is primarily related to biofilm infection, with incidence rates of 0.5% to 1.2% and 0.5% to 1.6%, respectively. The incidence of PJI is increasing with the increase in the number of patients undergoing joint replacement. Currently, the management of PJI typically involves surgery supplemented with antimicrobial therapy. Surgical procedures often require physical disruption or removal of the biofilm through surgical debridement, but this approach struggles to control recurrent infections, results in poor long-term prognosis, and increases patient suffering. Antibiotic therapy is also challenging, as the infecting bacteria can easily develop resistance and multidrug resistance. Due to the complex pathology of PJI, treatment is challenging, often requiring multiple surgical revisions and long-term, systemic antibiotic therapy. Repeated hospitalizations and prolonged mobility issues severely impact quality of life, and medical costs are several times, if not dozens of times, higher than those of patients without PJI. Furthermore, while antibiotics are essential for all PJI treatment options, the medical community lacks unified standards or research consensus regarding the timing, optimal duration, dosage, and route of administration of antibiotics during PJI treatment. Clinical protocols are often based on expert consensus or experience, leading to an urgent need for high-quality, effective, and reliable (non-surgical) antimicrobial treatments.
[0003] Summary of the Invention
[0004] The present invention provides a more effective treatment method to overcome the shortcomings of the existing technology for treating periprosthetic joint infection.
[0005] In one aspect, the present application provides a method for preventing or treating periprosthetic joint infection (PJI), or alleviating the PJI-related conditions, the method comprising administering a therapeutic agent to the joint cavity of a patient in need thereof, the therapeutic agent comprising a compound represented by formula (I) and / or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated product thereof,
[0006] In some embodiments, the method comprises administering the therapeutic agent to the joint cavity of the patient in need thereof at a dosing frequency selected from the group consisting of once a day, once every 2 days, once every 3 days, once every 4 days, once every 5 days, once every 6 days, and once every 7 days.
[0007] In some embodiments, the method comprises administering the therapeutic agent to the joint cavity of the patient in need thereof for 1 day to about 6 months, wherein the dosing frequency of the therapeutic agent remains the same or changes during the 1 day to about 6 months.
[0008] In some embodiments, the therapeutic agent is administered to the patient in need thereof by one or more intra-articular injections in a single administration.
[0009] In some embodiments, the therapeutic agent comprises from about 10 mg to about 300 mg of the compound of formula (I) and / or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated form thereof in a single administration.
[0010] In some embodiments, the therapeutic agent further comprises other components selected from other drugs, pharmaceutically acceptable carriers, solvents, and buffers.
[0011] In some embodiments, the other components and the compound of Formula (I) and / or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, metabolites or deuterated substances thereof are not mixed with each other.
[0012] In some embodiments, one or more of the other components are mixed with the compound of formula (I) and / or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated product thereof.
[0013] In some embodiments, the method further comprises administering to the patient in need thereof an effective amount of an additional therapeutic agent.
[0014] In some embodiments, the periprosthetic joint infection (PJI) is caused by a Gram-positive bacterial infection.
[0015] In some embodiments, the periprosthetic joint infection (PJI) is caused by Staphylococcus aureus infection and / or coagulase-negative staphylococcal infection.
[0016] In some embodiments, the periprosthetic joint infection (PJI) comprises early PJI, acute hematogenous PJI, and chronic PJI.
[0017] In some embodiments, the periprosthetic joint infection is an early PJI occurring within about 3 months after prosthetic joint replacement surgery or an acute hematogenous PJI occurring within about 4 weeks after the surgery in the patient in need thereof.
[0018] In some embodiments, the patient in need thereof includes subjects who have not yet developed the periprosthetic joint infection (PJI) but are at risk of developing the PJI.
[0019] In some embodiments, the method comprises administering the therapeutic agent to the joint cavity of the subject for 1 day to 14 days.
[0020] In some embodiments, the first day of the period lasting from 1 day to 14 days is the day on which the subject receives prosthetic joint replacement surgery.
[0021] On the other hand, the present application provides the use of a compound represented by formula (I) and / or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated product thereof in the preparation of a therapeutic agent, wherein the therapeutic agent is used to prevent or treat periprosthetic joint infection (PJI) or alleviate the PJI-related symptoms, and the therapeutic agent is formulated for intra-articular administration to a patient in need.
[0022] In some embodiments, the therapeutic agent is formulated for administration to the joint cavity of the patient in need thereof at a dosing frequency selected from the following: once a day, once every 2 days, once every 3 days, once every 4 days, once every 5 days, once every 6 days, and once every 7 days.
[0023] In some embodiments, the therapeutic agent is formulated for administration to the joint cavity of the patient in need thereof for 1 day to about 6 months, wherein the therapeutic agent is formulated for administration to the patient in need thereof at the same or different dosing frequencies during the 1 day to about 6 months.
[0024] In some embodiments, the therapeutic agent is formulated for one or more intra-articular injections in a single administration.
[0025] In some embodiments, the therapeutic agent comprises from about 10 mg to about 300 mg of the compound of formula (I) and / or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated form thereof in a single administration.
[0026] In some embodiments, the therapeutic agent further comprises other components selected from other drugs, pharmaceutically acceptable carriers, solvents, and buffers.
[0027] In some embodiments, the other components and the compound of Formula (I) and / or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, metabolites or deuterated substances thereof are not mixed with each other.
[0028] In some embodiments, one or more of the other components are mixed with the compound of formula (I) and / or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated product thereof.
[0029] In some embodiments, the therapeutic agent is formulated for co-administration with an effective amount of another therapeutic agent to the patient in need thereof.
[0030] In some embodiments, the periprosthetic joint infection (PJI) is caused by a Gram-positive bacterial infection.
[0031] In some embodiments, the periprosthetic joint infection (PJI) is caused by Staphylococcus aureus infection and / or coagulase-negative staphylococcal infection.
[0032] In some embodiments, the periprosthetic joint infection (PJI) comprises early PJI, acute hematogenous PJI, and chronic PJI.
[0033] In some embodiments, the periprosthetic joint infection is an early PJI occurring within about 3 months after the patient in need thereof undergoes artificial joint prosthesis replacement surgery or an acute hematogenous PJI occurring within about 4 weeks after the surgery.
[0034] In some embodiments, the patient in need thereof includes subjects who have not yet developed the periprosthetic joint infection (PJI) but are at risk of developing the PJI.
[0035] In some embodiments, the therapeutic agent is formulated for administration to the subject's joint cavity for 1 day to 14 days.
[0036] In some embodiments, the first day of the period lasting from 1 day to 14 days is the day on which the subject receives prosthetic joint replacement surgery. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] The specific features of the inventions of this application are set forth in the appended claims. The features and advantages of the inventions of this application can be better understood by referring to the exemplary embodiments described in detail below and the accompanying drawings. A brief description of the drawings is as follows:
[0038] Figures 1A-1B show the colony counts in metal implants and bone joints of mice after administration of the treatment regimen of the present application and other treatment regimens, wherein the horizontal axis from left to right represents the high, medium, and low dose IA groups of the compound of formula (I), the high, medium, and low dose IP groups of the compound of formula (I), the vancomycin IA group, the vehicle control group, the blank group infected for 14 days, and the blank group infected for 7 days.
[0039] Figures 2A-2B show the state of the implanted joint prosthesis of rats under electron microscopy (A) and the pathological H&E staining results of the rat synovial soft tissue after administration of the treatment regimen of the present application and other treatment regimens (B).
[0040] FIG3 shows the drug concentration-time curves of the compound of formula (I) in plasma and joint fluid samples after administration of the treatment regimen of the present application to male and female beagle dogs. DETAILED DESCRIPTION
[0041] The following describes the implementation of the present invention through specific embodiments. People familiar with this technology can easily understand other advantages and effects of the present invention from the contents disclosed in this specification.
[0042] Definition of terms
[0043] In this application, the term "patient in need thereof" generally includes human patients and other mammalian subjects receiving prophylactic or therapeutic treatment, including but not limited to non-human primates, experimental animals such as rabbits, dogs, rats and mice, and other animals. These "patients in need thereof" can be, for example, subjects with a confirmed specific disease, subjects receiving treatment related to a specific disease, subjects with a tendency or risk of developing a specific disease, etc.
[0044] As used herein, the term "subject at risk" generally refers to an individual or subject who, based on certain risk factors, has a higher probability of developing a particular disease or condition. For example, in this application, such risk factors may include, but are not limited to, a lack of resistance to a particular infection or infectious disease, and previous, current, or planned exposure to an environment with infectious conditions. In certain embodiments, such subjects may be asymptomatic or exhibit symptoms that have not been formally diagnosed.
[0045] In this application, the term "administer" generally refers to introducing the drug or a composition comprising the drug into the patient's body by any introduction or delivery route. Any method known to those skilled in the art for contacting cells, organs or tissues with the drug or its composition can be used. The term "single administration" can be divided into one, two or more doses in a suitable form for administration at one, two or more times during a certain time period.
[0046] In this application, the term "therapeutic agent" generally refers to a compound, a mixture of compounds, a composition, a biomacromolecule or an extract made from a biological material that can induce a desired therapeutic effect, prevent a certain disease, or alleviate a related disease when properly administered to a patient.
[0047] In this application, the term "pharmaceutically acceptable salt" generally refers to conventional acid- or base-addition salts that retain the biological efficacy and properties of the parent compound, such as the compound of formula (I). By way of example only, acid-addition salts can be formed with suitable non-toxic organic or inorganic acids, sample acid-addition salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid, and those derived from organic acids such as p-toluenesulfonic acid, naphthalenesulfonic acid, naphthalenedisulfonic acid, methanesulfonic acid, ethanesulfonic acid, trifluoroacetic acid, etc.; base-addition salts include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium and magnesium salts, and salts derived from organic bases such as primary, secondary and tertiary amines. Chemical modification of (drug) compounds into salts is a well-known technique for pharmaceutical chemists to obtain improved physical and chemical stability, hygroscopicity, fluidity and solubility of the compounds. See, e.g., Ansel, H., et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 6th ed., 1995.
[0048] In this application, the terms "solvate" and "solvate" are used interchangeably and generally refer to an association or complex of one or more solvent molecules with the salt-type compound of the present application. Examples of solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine. The term "hydrate" generally refers to a complex in which the solvent molecule is water.
[0049] In the present application, the term "prodrug" generally refers to the prodrug substance that can be metabolized to form a substance having the structure of the compound of the present application after being administered to a patient; the term "metabolite" generally refers to the substance obtained by the metabolism of the compound of the present application after being administered to a patient, and the prodrugs and metabolites contained in such derivatives are included in the scope of the invention of the present application.
[0050] In this application, the terms "deuterated compound" and "deuterated compound" are used interchangeably, and generally refer to a new compound obtained by replacing one or more hydrogen atoms in an organic compound with a deuterium atom.
[0051] In this application, the term "drug" generally refers to a molecule with the desired biological effect. The drug can be preventive or therapeutic. The drug may include, but is not limited to: protein molecules, including but not limited to peptides, polypeptides, proteins, including post-translationally modified proteins, fusion proteins, antibodies, etc.; small molecules, including inorganic or organic compounds; nucleic acid molecules, including but not limited to double-stranded or single-stranded DNA, or double-stranded or single-stranded RNA (such as antisense (molecules), RNAi, etc.), intron sequences, triple-helical nucleic acid molecules and aptamers; or vaccines (such as Lister and non-Lister vaccines). The drug can be obtained from any known organism (including but not limited to: animals, plants, bacteria, fungi and protozoa or viruses) or a synthetic molecule library.
[0052] In this application, the term "pharmaceutically acceptable carrier" generally refers to one or more non-toxic materials that do not interfere with the effectiveness of the biological activity of the active ingredient. Such preparations can conventionally contain salts, buffers, preservatives, compatible carriers and optionally other therapeutic agents. Such pharmaceutically acceptable preparations can also include compatible solid or liquid fillers, diluents or encapsulating materials suitable for administration to people. Other envisioned carriers, excipients, and / or additives that can be used in the formulations described herein may include, for example, flavorings, antimicrobials, sweeteners, antioxidants, antistatic agents, lipids, protein excipients (such as serum albumin, gelatin, casein), salt-forming counterions (such as sodium), etc. These and other known pharmaceutical carriers, excipients and / or additives suitable for use in the formulations described herein are known in the art and are listed, for example, in "Remington: The Science & Practice of Pharmacy," 21st edition, Lippincott Williams & Wilkins (2005) and "Physician's Desk Reference," 60th edition, Medical Economics, Montvale, New Jersey (2005). Suitable pharmaceutically acceptable carriers can be routinely selected for the desired or required mode of administration, solubility and / or stability.
[0053] In this application, the term "mixing" generally refers to the process of combining one or more compounds, cells, molecules, etc. in the same area. This can be done, for example, in a test tube, petri dish, or any container that allows mixing of one or more compounds, cells, or molecules.
[0054] In this application, the term "appears..." generally refers to a patient or subject showing clinical signs of a particular disease, for example, in this application, it may refer to showing clinical signs of early, acute hematogenous or chronic periprosthetic joint infection.
[0055] In this application, the term "comprising" generally refers to including the features specified but not excluding other elements. The terms "above" and "below" generally refer to including the number.
[0056] In this application, the term "selected from" generally refers to the selected objects and all combinations thereof. For example, "selected from (:) A, B and C" means all combinations of A, B and C, for example, A, B, C, A+B, A+C, B+C or A+B+C.
[0057] In this application, the terms "effective amount" or "effective dose" are used interchangeably and generally refer to an amount sufficient to achieve or at least partially achieve the desired therapeutic effect. When used in a patient in need, it generally refers to an amount sufficient to cure a patient already suffering from a disease or at least partially prevent the disease and its complications. The effective amount for this use will depend on the severity of the patient's infection and the overall state of the patient's own immune system.
[0058] In this application, the term "co-administration" generally refers to the administration of a therapeutic agent described herein with another therapeutic agent or drug as a single formulation or as multiple independent formulations. Co-administration can be simultaneous or sequential in any order, for example, preferably for a period of time while two (or all) active pharmaceutical ingredients simultaneously exert their biological activities. The therapeutic agent described herein and the other therapeutic agent are not necessarily administered by the same route of administration.
[0059] In this application, the term "about" or "approximately" is generally within an acceptable error range for a particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, "about" or "approximately" can mean within 1 or more than 1 standard deviation according to the practice in the art. Alternatively, "about" or "approximately" can mean a range of up to 10% or 20% (i.e., ±10% or ±20%). For example, about 3 mg can include any amount between 2.7 mg and 3.3 mg (for 10%) or between 2.4 mg and 3.6 mg (for 20%). In addition, particularly with respect to biological systems or processes, the term can mean a value of up to one order of magnitude or a value of up to 5 times. When a specific value or composition is provided in this specification and the appended claims, unless otherwise indicated, the meaning of "about" or "approximately" should be assumed to be within an acceptable error range for that specific value or composition.
[0060] Detailed Description of the Invention
[0061] On the one hand, the present application provides a method for treating periprosthetic joint infection (PJI), which may include administering a therapeutic agent to the joint cavity of a patient in need thereof, wherein the therapeutic agent may comprise a compound represented by formula (I) and / or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated product thereof.
[0062] In some embodiments, the method can comprise administering the therapeutic agent to the joint cavity of the patient in need thereof at a dosing frequency selected from once a day, once every 2 days, once every 3 days, once every 4 days, once every 5 days, once every 6 days, and once every 7 days.
[0063] In some embodiments, the method may include administering the therapeutic agent to the joint cavity of the patient in need for 1 day to about 6 months, wherein the frequency of administration of the therapeutic agent may remain the same or change during the duration of 1 day to about 6 months. For example, the method may include administering the therapeutic agent to the joint cavity of the patient in need for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 26 days, 27 days, 28 days, 29 days, 30 days (1 month), 31 days, 32 days, 33 days, 34 days, 35 days, 36 days, 37 days, 38 days, 39 days, 40 days, 41 day, 42 days, 43 days, 44 days, 45 days, 46 days, 47 days, 48 days, 49 days, 50 days, 51 day, 52 days, 53 days, 54 days, 55 days, 56 days, 57 days, 58 days, 59 days, 60 days (2 months), about 3 months, about 4 months, about 5 months and about 6 months. During the number of days of continuous administration of the therapeutic agent, the same frequency of administration of the therapeutic agent can be maintained, or the frequency of administration can be changed according to the actual needs of the patient or in accordance with the doctor's advice.
[0064] In some embodiments, the therapeutic agent is administered to the patient in need thereof by one or more intra-articular injections in a single administration. For example, the therapeutic agent is administered to the articular cavity of the patient in need thereof by one, two, three, four, five, six, or more bolus injections in a single administration, wherein the two or more bolus injections may be performed continuously or at the same or different time intervals; the therapeutic agent administered by the two or more bolus injections may contain the same or different amounts of the compound of formula (I) and / or its pharmaceutically acceptable salts, hydrates, solvates, prodrugs, metabolites, or deuterated derivatives.
[0065] In some embodiments, the therapeutic agent comprises from about 10 mg to about 300 mg of the compound shown in formula (I) and / or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated substance in a single administration. For example, the therapeutic agent may comprise about 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 210 mg, 220 mg, 230 mg, 240 mg, 250 mg, 260 mg, 270 mg, 280 mg, 290 mg or 300 mg of the compound of formula (I) and / or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated substance in a single administration.
[0066] In some embodiments, the therapeutic agent further comprises other components selected from other drugs, pharmaceutically acceptable carriers, solvents and buffers. For example, the other components and the compound of formula (I) and / or its pharmaceutically acceptable salts, hydrates, solvates, prodrugs, metabolites or deuterated substances do not mix with each other. For example, the not mixing with each other may refer to that the other components and the compound of formula (I) and / or its pharmaceutically acceptable salts, hydrates, solvates, prodrugs, metabolites or deuterated substances are placed in different containers and / or devices. For example, the not mixing with each other may refer to that the container or device for placing the compound of formula (I) and / or its pharmaceutically acceptable salts, hydrates, solvates, prodrugs, metabolites or deuterated substances in the therapeutic agent, and the container or device for placing other components are placed in different storage spaces and / or different storage conditions. For example, the term "non-mixing with each other" may refer to that the other components and the compound of formula (I) and / or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated substance are separately packaged and stored in specific measurement units in their respective containers and / or devices. For example, the term "non-mixing with each other" may refer to that the other components and the compound of formula (I) and / or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated substance are mixed only before using the therapeutic agent, and the mixing process may include using a mixing device included or not included in the therapeutic agent, transferring the other components and the compound of formula (I) and / or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated substance to a container or device where another component is placed for mixing, and / or transferring the other components and the compound of formula (I) and / or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated substance to another container or device for mixing.
[0067] In some embodiments, the therapeutic agent comprises other components selected from other drugs, pharmaceutically acceptable carriers, solvents and buffers, and one or more of the other components are mixed with the compound of formula (I) and / or its pharmaceutically acceptable salts, hydrates, solvates, prodrugs, metabolites or deuterated substances. For example, the mutual mixing may refer to one or more of the other components being mixed with the compound of formula (I) and / or its pharmaceutically acceptable salts, hydrates, solvates, prodrugs, metabolites or deuterated substances and placed in the same container or device. For example, the mutual mixing may refer to one or more of the other components being mixed with the compound of formula (I) and / or its pharmaceutically acceptable salts, hydrates, solvates, prodrugs, metabolites or deuterated substances and then stored in the same or different containers or devices in specific metered units. For example, the mutual mixing may refer to that after one or more of the other components are mixed with the compound of formula (I) and / or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated substance, further sufficient mixing (for example, vigorous shaking is required to ensure sufficient mixing) is required before the therapeutic agent is used.
[0068] In some embodiments, the method further comprises administering an effective amount of other therapeutic agents to the patient in need. For example, the method further comprises administering an effective amount of other therapeutic agents to the patient by injection (mainly referring to non-intra-articular routes, for example, intravenous injection, intramuscular injection and / or subcutaneous injection), oral administration, (except for the joint cavity) intracavity administration, enteral administration and / or transdermal absorption. For example, the other therapeutic agents may be selected from antimicrobial agents, anesthetics, analgesics, sedatives, hormones, anti-inflammatory drugs, anticoagulants, platelet aggregation inhibitors, antipyretics, cell membrane permeation agents and muscle relaxants.
[0069] The pathogenic bacteria spectrum of periprosthetic joint infection is complex and can be caused by a single pathogen or a mixed infection of multiple pathogens. In some embodiments, the periprosthetic joint infection can be caused by Gram-positive bacteria infection. For example, the periprosthetic joint infection can be caused by Staphylococcus aureus infection and / or coagulase-negative Staphylococcus infection. Specifically, the coagulase-negative Staphylococcus can be selected from Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus xylinus, Staphylococcus haemolyticus, Staphylococcus capitis, Staphylococcus warneri, Staphylococcus mimicus, Staphylococcus xylosus and Staphylococcus apes. In the present application, the Gram-positive bacteria can also include its resistant strains, for example, the resistant strain can be resistant to rifamycin (for example, rifampicin) single resistance, resistant to quinolone or quinolizinone single resistance, or resistant to rifamycin and quinolizinone double resistance. For example, the resistant strains may also be resistant to other antibiotics, including resistance to macrolides such as clarithromycin, azithromycin, and roxithromycin; resistance to nitroimidazoles such as metronidazole, ornidazole, premanide, and delamanide; resistance to aminoglycosides such as streptomycin and amikacin; resistance to β-lactams such as methicillin, ampicillin, and amoxicillin; resistance to tetracyclines such as tetracycline, tigecycline, and minocycline; resistance to oxazolidinones such as linezolid and tedizolid; resistance to nitrofurans such as furazolidone; resistance to polypeptides such as vancomycin and polymyxins; resistance to diarylquinolines such as bedaquiline and clofazimine, etc. In the present application, the diagnosis of whether the patient suffers from periprosthetic joint infection can be made by using diagnostic methods and diagnostic criteria known in the art, combined with the patient's detailed medical history and physical examination, serology, microbiology, pathology and imaging examination results.
[0070] In some embodiments, the periprosthetic joint infection (PJI) comprises early PJI, acute hematogenous PJI, and chronic PJI. Due to the complexity and variability of the pathogenesis and pathogenesis of PJI, there is no unified standard for the diagnosis and classification of PJI in this field. However, based on the clinical characteristics of PJI and the time of infection, the commonly used classification methods include the Tsukayama method (Tsukayama DT, Estrada R, Gustilo RB. Infection after total hip arthroplasty. A study of the treatment of one hundred and six infections [J]. J Bone Joint Surg Am, 1996, 78 (4): 512-523; and Tsuk ayama DT, Goldberg VM, Kyle R. Diagnoses and management of infection after total knee arthroplasty [J]. J Bone Joint Surg Am, 2003, 85A (1): 75-80.), the Zimmerli method (Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections [J]. N Engl J Med, 2004, 351(16):1645-1654.), Coventry method (Coventry MB. Treatment of infections occurring in total hip surgery. Orthop Clin North Am 1975; 6:991-1003.), and Barrett method (Barrett L, Atkins B. The clinical presentation of prosthetic joint infection. J Antimicrob Chemother. 2014 Sep; 69 Suppl 1:i25-7.), etc. For example, Zimmerli et al. define PJI occurring within 3 months after artificial joint prosthesis replacement surgery as early PJI infection, define PJI occurring between 3 and 24 months after the surgery as delayed or mid-term PJI infection, and define PJI occurring after 24 months after the surgery as late infection. For example, the periprosthetic joint infection may also be acute hematogenous PJI occurring within about 4 weeks after the surgery.
[0071] In some embodiments, the patient in need may include a subject in which the periprosthetic joint infection (PJI) has not occurred but there is a risk of the PJI occurring. For example, the method may include administering the therapeutic agent to the joint cavity of the subject for 1 to 14 consecutive days. Specifically, the method may include administering the therapeutic agent to the joint cavity of the subject for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days or 14 days. During the continuous number of days, the same frequency of administering the therapeutic agent may be maintained, or the frequency of administration may be changed according to the actual needs of the subject or in accordance with the doctor's advice. For example, the first day of the continuous 1 to 14 days is the day on which the subject undergoes joint prosthesis replacement surgery. In the present application, it can be determined whether the subject is at risk of PJI based on the subject's detailed medical history, physical examination, diagnostic report, treatment plan planning, etc.
[0072] On the other hand, the present application provides the use of a compound represented by formula (I) and / or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated product thereof in the preparation of a therapeutic agent, wherein the therapeutic agent is used to treat periprosthetic joint infection, and the therapeutic agent is formulated for intra-articular administration to a patient in need.
[0073] In some embodiments, the therapeutic agent is formulated for administration to the joint cavity of the patient in need thereof at a dosing frequency selected from the following: once a day, once every 2 days, once every 3 days, once every 4 days, once every 5 days, once every 6 days, and once every 7 days.
[0074] In some embodiments, the therapeutic agent is formulated to be suitable for administering the therapeutic agent to the joint cavity of the patient in need for 1 day to about 6 months, wherein the therapeutic agent is formulated to be suitable for administering the therapeutic agent to the patient in need with the same or different dosing frequencies for the duration of 1 day to about 6 months. For example, the therapeutic agent can be formulated to be suitable for administering the therapeutic agent to the joint cavity of the patient in need for a duration optionally selected from the following days: 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 26 days, 27 days, 28 days, 29 days, 30 days (1 month), 31 days, 32 days, 33 days, 34 days, 35 days, 36 days, 37 days , 38 days, 39 days, 40 days, 41 days, 42 days, 43 days, 44 days, 45 days, 46 days, 47 days, 48 days, 49 days, 50 days, 51 days, 52 days, 53 days, 54 days, 55 days, 56 days, 57 days, 58 days, 59 days, 60 days (2 months), about 3 months, about 4 months, about 5 months and about 6 months. During the continuous number of days, the therapeutic agent is formulated to maintain the same dosing frequency, and can also be formulated to be administered to the patient in need with different dosing frequencies according to the actual needs of the patient or in accordance with the doctor's advice.
[0075] In some embodiments, the therapeutic agent is formulated for one or more intra-articular injections in a single administration. For example, the therapeutic agent is formulated for administration to the articular cavity of the patient in need thereof by 1, 2, 3, 4, 5, 6 or more boluses in a single administration, wherein the 2 or more boluses may be administered by formulating the therapeutic agent for continuous boluses or by formulating the therapeutic agent for boluses at the same or different time intervals; the therapeutic agent administered by the 2 or more boluses may comprise the same or different amounts of the compound of formula (I) and / or its pharmaceutically acceptable salts, hydrates, solvates, prodrugs, metabolites or deuterated derivatives.
[0076] In some embodiments, the therapeutic agent comprises about 10 mg to about 300 mg of the compound shown in formula (I) and / or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated substance in a single administration. For example, the compound of formula (I) and / or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated substance included in the therapeutic agent in a single administration can be about 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 210 mg, 220 mg, 230 mg, 240 mg, 250 mg, 260 mg, 270 mg, 280 mg, 290 mg or 300 mg.
[0077] In some embodiments, the therapeutic agent further comprises other components selected from other drugs, pharmaceutically acceptable carriers, solvents and buffers. For example, the other components and the compound of formula (I) and / or its pharmaceutically acceptable salts, hydrates, solvates, prodrugs, metabolites or deuterated substances do not mix with each other. For example, the not mixing with each other may refer to that the other components and the compound of formula (I) and / or its pharmaceutically acceptable salts, hydrates, solvates, prodrugs, metabolites or deuterated substances are placed in different containers and / or devices. For example, the not mixing with each other may refer to that the container or device for placing the compound of formula (I) and / or its pharmaceutically acceptable salts, hydrates, solvates, prodrugs, metabolites or deuterated substances in the therapeutic agent, and the container or device for placing other components are placed in different storage spaces and / or different storage conditions. For example, the term "non-mixing with each other" may refer to that the other components and the compound of formula (I) and / or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated substance are separately packaged and stored in specific measurement units in their respective containers and / or devices. For example, the term "non-mixing with each other" may refer to that the other components and the compound of formula (I) and / or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated substance are mixed only before using the therapeutic agent, and the mixing process may include using a mixing device included or not included in the therapeutic agent, transferring the other components and the compound of formula (I) and / or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated substance to a container or device where another component is placed for mixing, or transferring the other components and the compound of formula (I) and / or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated substance to another container or device for mixing.
[0078] In some embodiments, the therapeutic agent comprises other components selected from other drugs, pharmaceutically acceptable carriers, solvents and buffers, and one or more of the other components are mixed with the compound of formula (I) and / or its pharmaceutically acceptable salts, hydrates, solvates, prodrugs, metabolites or deuterated substances. For example, the mutual mixing may refer to one or more of the other components being mixed with the compound of formula (I) and / or its pharmaceutically acceptable salts, hydrates, solvates, prodrugs, metabolites or deuterated substances and placed in the same container or device. For example, the mutual mixing may refer to one or more of the other components being mixed with the compound of formula (I) and / or its pharmaceutically acceptable salts, hydrates, solvates, prodrugs, metabolites or deuterated substances and then stored in the same or different containers or devices in specific metered units. For example, the mutual mixing may refer to that after one or more of the other components are mixed with the compound of formula (I) and / or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated substance, further sufficient mixing (for example, vigorous shaking is required to ensure sufficient mixing) is required before the therapeutic agent is used.
[0079] In some embodiments, the therapeutic agent is formulated to be suitable for co-administration with an effective amount of other therapeutic agents to the patient in need. For example, the therapeutic agent can be formulated to be suitable for co-administration with an effective amount of other therapeutic agents to the patient in need, wherein the other therapeutic agents can be administered by injection (mainly referring to non-intra-articular routes, for example, intravenous injection, intramuscular injection and / or subcutaneous injection), oral administration, (except for the joint cavity) intracavity administration, enteral administration and / or transdermal absorption to the patient. For example, the other therapeutic agents can be selected from antibacterial agents, anesthetics, analgesics, sedatives, hormones, anti-inflammatory drugs, anticoagulants, platelet aggregation inhibitors, antipyretics, cell membrane permeation agents and muscle relaxants.
[0080] In some embodiments, the periprosthetic joint infection (PJI) is caused by gram-positive bacteria infection. For example, the periprosthetic joint infection can be caused by Staphylococcus aureus infection and / or coagulase-negative staphylococcus infection. Specifically, the coagulase-negative staphylococcus can be selected from Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus xylinus, Staphylococcus haemolyticus, Staphylococcus capitis, Staphylococcus warneri, Staphylococcus mimicus, Staphylococcus xylosus and Staphylococcus apes. In the present application, the gram-positive bacteria can also include its resistant strains, for example, the resistant strains can be resistant to rifamycin (for example, rifampicin) single resistance, resistant to quinolone or quinolizinone single resistance or resistant to rifamycin and quinolizinone double resistance. For example, the resistant strains may also be resistant to other antibiotics, including resistance to macrolides such as clarithromycin, azithromycin, and roxithromycin; resistance to nitroimidazoles such as metronidazole, ornidazole, premanide, and delamanide; resistance to aminoglycosides such as streptomycin and amikacin; resistance to β-lactams such as methicillin, ampicillin, and amoxicillin; resistance to tetracyclines such as tetracycline, tigecycline, and minocycline; resistance to oxazolidinones such as linezolid and tedizolid; resistance to nitrofurans such as furazolidone; resistance to polypeptides such as vancomycin and polymyxins; resistance to diarylquinolines such as bedaquiline and clofazimine, etc. In the present application, the diagnosis of whether the patient in need suffers from periprosthetic joint infection can be made by using diagnostic methods and diagnostic criteria known in the art, combined with the patient's detailed medical history and physical examination, serology, microbiology, pathology and imaging examination results.
[0081] In some embodiments, the periprosthetic joint infection (PJI) includes early PJI, acute hematogenous PJI, and chronic PJI. For example, PJI occurring within 3 months after artificial joint prosthesis replacement surgery is defined as early PJI infection, PJI occurring between 3 and 24 months after the surgery is defined as delayed or mid-term PJI infection, and PJI occurring after 24 months after the surgery is defined as late infection (Zimmerli et al., 2004). For example, the periprosthetic joint infection can be acute hematogenous PJI occurring within about 4 weeks after the surgery.
[0082] In some embodiments, the patient in need may include a subject who has not yet developed the periprosthetic joint infection (PJI) but is at risk of developing the PJI. For example, the therapeutic agent can be formulated to be suitable for continuous administration to the joint cavity of the subject for 1 to 14 days. Specifically, the therapeutic agent can be formulated to be suitable for continuous administration to the joint cavity of the subject for a number of days selected from the following: 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days and 14 days. During the continuous number of days, the therapeutic agent is formulated to be suitable for maintaining the same dosing frequency, or it can be formulated to be suitable for administration to the joint cavity of the subject at different dosing frequencies according to the actual needs of the subject or in accordance with the doctor's advice. For example, the first day of the continuous 1 to 14 days is the day on which the subject undergoes joint prosthesis replacement surgery. In the present application, whether the subject is at risk of PJI can be judged based on the subject's detailed medical history, physical examination, diagnostic report, treatment plan planning, etc.
[0083] Without intending to be bound by any theory, the following embodiments are merely intended to illustrate the methods and uses of the present application and are not intended to limit the scope of the present invention.
[0084] Example
[0085] Example 1
[0086] Evaluation of the efficacy of the therapeutic method in this application in mouse models
[0087] 1. Experimental Methods
[0088] This example used female mice aged 8-10 weeks and randomly divided them into groups. Before the start of drug treatment, each mouse underwent surgery to implant a metal implant into the femoral-tibial joint and to inoculate the joint cavity at the surgical site with methicillin-sensitive Staphylococcus aureus (MSSA, ATCC 6538 strain).
[0089] Wherein, the preparation of therapeutic agent is as follows:
[0090] (1) Compound of formula (I): In the therapeutic agent for intra-articular injection (IA), the compound is dissolved in 5% glucose aqueous solution (D5W) and formulated into the required concentration; in the therapeutic agent for intraperitoneal injection (IP), the compound is dissolved in a solvent system of ethanol / NaHCO3 / 6% Cremaphor and formulated into the required concentration; (2) Vancomycin: The drug is dissolved in sterile water for injection (WFI) and formulated into the required concentration to obtain a therapeutic agent for intra-articular injection.
[0091] The experimental design for evaluating the treatment effect is as follows:
[0092] Note: IA: intraarticular injection, IP: intraperitoneal injection, QD: once a day, BID: twice a day.
[0093] 2. Results Analysis
[0094] Samples were obtained from the surgical and inoculation sites of mice and the colony counts were counted on agar plates and converted into colony-forming units (CFU / tissue) by multiplying the colony count by the homogenate volume of the spot and the calculated colony count dilution (5-50 colonies / spot). The resulting value was expressed as log 10 CFU / tissue was displayed and used to calculate the mean and standard deviation (results are shown in Table 1).
[0095] Table 1 Analysis of bacterial colony counts in metal implants and bone joints of mice
[0096] The results in Table 1 and Figures 1A-1B show that on the 7th day after the start of treatment, the average colony counts of the metal implant and femur were 5.35 log 10 CFU and 6.77log 10 On day 14, the corresponding counts in the metal implant and femur of untreated control animals were 4.77 log 10 CFU and 6.88log 10 CFU.
[0097] Intraarticular administration of the compound of formula (I) showed a mean metal implant colony count and a mean femoral colony count that were 2.5-2.72 log lower than those of untreated control animals. 10 CFU and 1.71-3.42log 10CFU. Results for all Compound of Formula (I) IA dose groups were considered statistically significant compared to the control group (P < 0.0001), and the metal implant colony counts for the 45 mg / kg, 15 mg / kg, and 5 mg / kg Compound of Formula (I) IA dose groups, as well as the femoral colony counts for the 45 mg / kg and 15 mg / kg Compound of Formula (I) IA dose groups, were also determined to be statistically significant compared to the vancomycin IA dose group (P < 0.0001). Compared to the IP (BID) route of administration of the compound of formula (I), while 45 mg / kg demonstrated similar therapeutic efficacy, the femoral colony counts of the 15 mg / kg and 5 mg / kg IA (QD) dose groups were statistically significant compared to the IP administration of the compound of formula (I) at the same dose (P < 0.0001). The implant colony counts of the 15 mg / kg IA dose group were also statistically significant compared to the 15 mg / kg IP dose group (P < 0.0001). Intra-articular administration also reduces dosing frequency, offering advantages in improving patient compliance.
[0098] Example 2
[0099] Evaluation of the effect of the treatment method of this application on the rat PJI model
[0100] 1. Experimental Methods
[0101] This example used rats aged approximately 17 weeks. Prior to the start of the treatment, each rat underwent aseptic surgery to insert an artificial prosthesis into the knee joint. The joint cavity at the surgical site was then inoculated with methicillin-resistant Staphylococcus aureus (MRSA, ATCC43300 strain).
[0102] At the same time, the experimental groups and their experimental content settings are specifically designed as shown in the following table:
[0103] Note: The low-, medium-, and high-dose groups of the compound of formula (I) were all prepared to the required concentration using 5% glucose aqueous solution (D5W) on the day of use; vancomycin (clinically effective dose, equivalent to an effective dose of 44 mg / kg in rats) was prepared to the required concentration using sterile water for injection.
[0104] 2. Results Analysis
[0105] In this example, the MIC values (minimum inhibitory concentrations) of vancomycin and the compound of formula (I) against MRSA ATCC43300 were determined, and the MIC values were obtained. 万古霉素 0.5ug / mL and MIC 式(I)The concentration of the compound of formula (I) is 0.032 ug / mL, which means that the compound of formula (I) has a stronger bactericidal effect in vitro than vancomycin. The electron microscopy results shown in Figure 2A show that a large number of colonies and biofilms are formed on the prosthesis of the control infection group (solvent group). In the low-dose group of the compound of formula (I), more colonies can still be seen, and more microscopic proteins are covered around the bacteria; the microscopic proteins of the medium-dose group are distributed in a reticular manner, some of which are aggregated into bundles, and some individual bacteria are still present; the microscopic proteins of the high-dose group are evenly distributed and interspersed with individual cocci; the vancomycin-treated group still has more bacteria remaining, and the microscopic proteins are distributed in a reticular manner. The above results show that for bacteria colonized on the prosthesis, the medium and high-dose treatment groups of the compound of formula (I) have a stronger ability to inhibit bacteriostasis and biofilm growth than the vancomycin group.
[0106] The results of H&E staining of the pathological synovial soft tissue, shown in Figure 2B, showed that the synovium of the control infection group exhibited severe interstitial cell proliferation, increased cell layers, and inflammatory cell infiltration. The synovitis symptoms of the low-, medium-, and high-dose groups treated with vancomycin and the compound of Formula (I) showed varying degrees of improvement. In particular, the inflammatory cell infiltration in the synovium of the high-dose group of the compound of Formula (I) and the vancomycin group was significantly reduced, and the synovitis symptoms were significantly alleviated.
[0107] Table 2 shows the statistical results of sampling and CFU values (tissue bacterial load) of implanted joint prostheses (the primary evaluation site for PJI infection), bone tissue (the primary evaluation site for PJI infection), and soft tissue (a non-primary evaluation site for PJI infection) after treatment in each group. The results of the efficacy experiments showed that compared with the vehicle control group, the low, medium, and high dose groups of the compound of formula (I) all exhibited good bactericidal effects; compared with the vancomycin group, the low, medium, and high dose groups of the compound of formula (I) all exhibited superior bactericidal effects in prosthetic tissue and bone tissue, and the medium and high dose groups of the compound of formula (I) exhibited comparable bactericidal effects in soft tissue.
[0108] Table 2 Prosthesis CFU count results Note: ***Compared with the control group (Con), p < 0.001, there is a very significant difference; one-way ANOVA analysis method was used.
[0109] Summary: This example used S. aureus ATCC43300 to establish a stable rat prosthetic joint infection model and evaluated the intra-articular antibacterial activity of an injection of the compound of formula (I). The results showed that intra-articular administration of the compound of formula (I) effectively reduced the bacterial load in rat joint tissues, demonstrating dose-dependent bactericidal activity. Compared to the vancomycin-treated group, the medium- and high-dose groups exhibited enhanced bactericidal activity.
[0110] Example 3
[0111] Pharmacokinetic analysis of the treatment method of this application in male and female beagle dogs
[0112] This example uses a male and female beagle dog animal model test to evaluate the pharmacokinetic behavior after a single knee joint injection of the compound of formula (I). A total of 6 beagle dogs (3 males and 3 females) were selected for this test. The test animals were injected with 3 mg / kg of the compound of formula (I) into the left joint cavity, and 0.1 mL / kg of the solvent (5% glucose injection solution) was injected into the right joint cavity. Plasma samples were collected from the test animals before (0 hour) and 0.25 (15 minutes), 3, 9, 12, 24, 36, 48 and 72 hours after administration, and left knee joint fluid samples were collected 12, 36 and 60 hours after administration. The concentration of the compound of formula (I) in plasma and joint fluid samples was determined by high performance liquid chromatography-tandem mass spectrometry (LC-MS / MS).
[0113] Table 3 Pharmacokinetic parameters of single intra-articular injection in male and female beagle dogs
[0114] Note: (1) C max : peak concentration, T max : Peak time, T 1 / 2 : Elimination half-life, AUC: Systemic drug exposure, that is, the area under the plasma concentration-time curve, AUC 0-last : Area under the plasma concentration-time curve from time 0 to the last quantifiable time point; (2) AUC ratio = synovial fluid AUC 0-last / Plasma AUC 0-last , N / A: Not applicable.
[0115] According to the test results shown in Table 3, after the above injection regimen was performed on the articular cavity of beagle dogs, the peak concentration (C max ) were 736±247 ng / mL and 77400±81900 ng / mL, respectively, which were much higher than their MICs against Staphylococcus aureus (15 ng / mL) and Staphylococcus epidermidis (8 ng / mL). 90 The concentration in joint fluid is much higher than its biofilm bactericidal activity against Staphylococcus aureus and Epidermophyton spp. 90 values (2000ng / mL and 250ng / mL). And it has a high exposure in both plasma and joint fluid, AUC 0-last The values were 20800±7150ng·h / mL and 1000000±1050000ng·h / mL, respectively. The AUC 0-lastThe ratio was 46.1, indicating that the drug was concentrated in the synovial fluid, which is expected to reduce clinical side effects caused by higher systemic exposure.
Claims
1. A method for preventing or treating periprosthetic joint infection (PJI), or alleviating PJI-related conditions, the method comprising administering a therapeutic agent to the joint cavity of a patient in need thereof, the therapeutic agent comprising a compound represented by formula (I) and / or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated product thereof, 2. The method of claim 1, comprising administering the therapeutic agent to the joint cavity of the patient in need thereof at a dosing frequency selected from the following: once a day, once every 2 days, once every 3 days, once every 4 days, once every 5 days, once every 6 days, and once every 7 days.
3. The method according to any one of claims 1-2, comprising administering the therapeutic agent to the joint cavity of the patient in need thereof for a period of 1 day to about 6 months, wherein the frequency of administration of the therapeutic agent remains the same or changes during the period of 1 day to about 6 months.
4. The method according to any one of claims 1-3, wherein the therapeutic agent comprises from about 10 mg to about 300 mg of the compound of formula (I) and / or its pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated substance in a single administration.
5. The method according to any one of claims 1 to 4, wherein the therapeutic agent further comprises other components selected from other drugs, pharmaceutically acceptable carriers, solvents and buffers.
6. The method according to claim 5, wherein the other components and the compound of formula (I) and / or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, metabolites or deuterated substances thereof are not mixed with each other.
7. The method according to claim 5, wherein one or more of the other components are mixed with the compound of formula (I) and / or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite or deuterated product thereof.
8. The method of any one of claims 1-7, further comprising administering to the patient in need thereof an effective amount of an additional therapeutic agent.
9. The method according to any one of claims 1 to 8, wherein the periprosthetic joint infection (PJI) is caused by Gram-positive bacterial infection.
10. The method according to any one of claims 1 to 9, wherein the periprosthetic joint infection (PJI) is caused by Staphylococcus aureus infection and / or coagulase-negative staphylococcal infection.
11. The method according to any one of claims 1-10, wherein the periprosthetic joint infection (PJI) comprises early PJI, acute hematogenous PJI and chronic PJI.
12. The method according to any one of claims 1-11, wherein the periprosthetic joint infection (PJI) is an early PJI occurring within about 3 months after the patient in need undergoes a prosthetic joint replacement surgery or an acute hematogenous PJI occurring within about 4 weeks after the surgery.
13. The method according to any one of claims 1-12, wherein the patient in need thereof comprises a subject who has not yet developed the periprosthetic joint infection (PJI) but is at risk of developing the PJI.
14. The method of claim 13, comprising administering the therapeutic agent to a joint cavity of the subject for from 1 day to 14 days.
15. The method according to claim 14, wherein the first day of the period lasting from 1 day to 14 days is the day on which the subject receives joint prosthesis replacement surgery.
Citation Information
Patent Citations
(r / s) rifamycin derivatives, their preparation and pharmaceutical compositions
CN101031572A
Application of rifamycin-buprofezin coupling molecule and salt thereof as well as preparation
CN109464673A
Application of rifamycin-buprofezin coupling module and pharmaceutically acceptable salt thereof
CN109529045A
